These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 16816924)

  • 1. Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels.
    Kawata T; Imanishi Y; Kobayashi K; Onoda N; Okuno S; Takemoto Y; Komo T; Tahara H; Wada M; Nagano N; Ishimura E; Miki T; Ishikawa T; Inaba M; Nishizawa Y
    J Bone Miner Metab; 2006; 24(4):300-6. PubMed ID: 16816924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.
    Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y
    Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism.
    Imanishi Y; Kawata T; Kenko T; Wada M; Nagano N; Miki T; Arnold A; Inaba M
    Calcif Tissue Int; 2011 Jul; 89(1):29-35. PubMed ID: 21541686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinacalcet in hyperfunctioning parathyroid diseases.
    Imanishi Y; Inaba M; Kawata T; Nishizawa Y
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S7-S11. PubMed ID: 19765257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical issues regarding cinacalcet hydrochloride in Japan.
    Yokoyama K
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S12-4. PubMed ID: 19765252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.
    Ritter C; Miller B; Coyne DW; Gupta D; Zheng S; Brown AJ; Slatopolsky E
    Kidney Int; 2017 Nov; 92(5):1217-1222. PubMed ID: 28750928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cinacalcet upregulates calcium-sensing receptors of parathyroid glands in hemodialysis patients.
    Sumida K; Nakamura M; Ubara Y; Marui Y; Tanaka K; Takaichi K; Tomikawa S; Inoshita N; Ohashi K
    Am J Nephrol; 2013; 37(5):405-12. PubMed ID: 23594726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl.
    Nemeth EF; Heaton WH; Miller M; Fox J; Balandrin MF; Van Wagenen BC; Colloton M; Karbon W; Scherrer J; Shatzen E; Rishton G; Scully S; Qi M; Harris R; Lacey D; Martin D
    J Pharmacol Exp Ther; 2004 Feb; 308(2):627-35. PubMed ID: 14593085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
    de Francisco AL
    Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical application of calcimimetics].
    Nishi H; Fukagawa M
    Clin Calcium; 2004 May; 14(5):756-9. PubMed ID: 15577038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.
    Colloton M; Shatzen E; Miller G; Stehman-Breen C; Wada M; Lacey D; Martin D
    Kidney Int; 2005 Feb; 67(2):467-76. PubMed ID: 15673294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular and Clinical Aspects of the Target Therapy with the Calcimimetic Cinacalcet in the Treatment of Parathyroid Tumors.
    Mingione A; Verdelli C; Terranegra A; Soldati L; Corbetta S
    Curr Cancer Drug Targets; 2015; 15(7):563-74. PubMed ID: 26033088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD.
    Miller G; Davis J; Shatzen E; Colloton M; Martin D; Henley CM
    Nephrol Dial Transplant; 2012 Jun; 27(6):2198-205. PubMed ID: 22036941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
    Nagano N
    Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].
    Nakanishi S; Fukagawa M
    Clin Calcium; 2007 Jan; 17(1):88-92. PubMed ID: 17211098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism.
    Yamada S; Tokumoto M; Taniguchi M; Toyonaga J; Suehiro T; Eriguchi R; Fujimi S; Ooboshi H; Kitazono T; Tsuruya K
    Ther Apher Dial; 2015 Aug; 19(4):367-77. PubMed ID: 25851690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism].
    Vestergaard P; Nielsen LR; Mosekilde L
    Ugeskr Laeger; 2006 Jan; 168(1):29-32. PubMed ID: 16393559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcimimetics--fooling the calcium receptor.
    Ritz E
    Pediatr Nephrol; 2005 Jan; 20(1):15-8. PubMed ID: 15517414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous expression analysis of vitamin D receptor, calcium-sensing receptor, cyclin D1, and PTH in symptomatic primary hyperparathyroidism in Asian Indians.
    Varshney S; Bhadada SK; Saikia UN; Sachdeva N; Behera A; Arya AK; Sharma S; Bhansali A; Mithal A; Rao SD
    Eur J Endocrinol; 2013 Jul; 169(1):109-16. PubMed ID: 23660642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.